77 related articles for article (PubMed ID: 16483004)
1. Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practice.
Egervari K; Szollosi Z; Nemes Z; Kaczur V
Am J Clin Pathol; 2006 Jan; 125(1):155-6. PubMed ID: 16483004
[No Abstract] [Full Text] [Related]
2. Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practice.
Dolan M; Snover D
Am J Clin Pathol; 2005 May; 123(5):766-70. PubMed ID: 15981817
[TBL] [Abstract][Full Text] [Related]
3. Does using a higher cutoff for the percentage of positive cells improve the specificity of HER-2 immunohistochemical analysis in breast carcinoma?
Hameed O; Chhieng DC; Adams AL
Am J Clin Pathol; 2007 Nov; 128(5):825-9. PubMed ID: 17951206
[TBL] [Abstract][Full Text] [Related]
4. Human epidermal growth factor receptor 2 testing in breast cancer.
Vang Nielsen K; Jørgensen JT; Schønau A; Øster A
J Clin Oncol; 2007 Sep; 25(25):4020; author reply 4021-3. PubMed ID: 17761991
[No Abstract] [Full Text] [Related]
5. Increased risk of brain metastases in patients with HER-2/neu-positive breast carcinoma.
Altaha R; Crowell E; Hobbs G; Higa G; Abraham J
Cancer; 2005 Feb; 103(3):442-3. PubMed ID: 15578684
[No Abstract] [Full Text] [Related]
6. Current status of HER2 testing: caught between a rock and a hard place.
Schnitt SJ; Jacobs TW
Am J Clin Pathol; 2001 Dec; 116(6):806-10. PubMed ID: 11764067
[No Abstract] [Full Text] [Related]
7. Re: How do you tell whether a breast cancer is HER2 positive? Ongoing studies keep debate in high gear.
Moelans CB; van Diest PJ
J Natl Cancer Inst; 2011 Apr; 103(8):698-9. PubMed ID: 21406657
[No Abstract] [Full Text] [Related]
8. Luminal B breast tumors are not HER2 positive.
Bhargava R; Dabbs DJ
Breast Cancer Res; 2008; 10(5):404; author reply 405. PubMed ID: 18831725
[No Abstract] [Full Text] [Related]
9. Correspondence re: Jimenez RE, Wallis T, Tabasczka P, Visscher DW. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 2000;13:37-45.
Hugh J; Barley R; Dabbagh L
Mod Pathol; 2001 Mar; 14(3):263. PubMed ID: 11266538
[No Abstract] [Full Text] [Related]
10. Fluorescent in situ hybridization as a primary test for HER2 status in breast cancer: controversies.
Arena V; Pennacchia I; Monego G; Carbone A; Capelli A
J Clin Oncol; 2010 Feb; 28(5):e83-4; author reply e85-8. PubMed ID: 20065180
[No Abstract] [Full Text] [Related]
11. The quality of Her-2/Neu predictive immunohistochemistry: something FISHy?
Tubbs RR; Stoler MH
Mod Pathol; 2000 Jan; 13(1):1-3. PubMed ID: 10658903
[No Abstract] [Full Text] [Related]
12. Tissue microarray technology in the routine assessment of HER-2 status in invasive breast cancer: a prospective study of the use of immunohistochemistry and fluorescence in situ hybridization.
Graham AD; Faratian D; Rae F; Thomas JS
Histopathology; 2008 Jun; 52(7):847-55. PubMed ID: 18494613
[TBL] [Abstract][Full Text] [Related]
13. Laboratory analysis of HER-2/neu: search for the optimal testing strategy.
Killeen JL
Hawaii Med J; 2003 Aug; 62(8):173-5. PubMed ID: 14533350
[No Abstract] [Full Text] [Related]
14. HER-2/neu analysis in breast cancer bone metastases.
Zustin J; Boddin K; Tsourlakis MC; Burandt E; Mirlacher M; Jaenicke F; Izbicki J; Ruether W; Rueger JM; Bokemeyer C; Simon R; Sauter G
J Clin Pathol; 2009 Jun; 62(6):542-6. PubMed ID: 19474354
[TBL] [Abstract][Full Text] [Related]
15. Controversies in the assessment of HER-2: more questions than answers.
Leong TY; Leong AS
Adv Anat Pathol; 2006 Sep; 13(5):263-9. PubMed ID: 16998320
[TBL] [Abstract][Full Text] [Related]
16. Human epidermal growth factor receptor 2 testing in breast cancer: 30% versus 10% cutoff for immunohistochemistry.
Hameed O; Chhieng D; Adams AL
J Clin Oncol; 2008 Mar; 26(9):1571. PubMed ID: 18349417
[No Abstract] [Full Text] [Related]
17. Surgical specimen can be replaced by core samples in assessment of ER, PR and HER-2 for invasive breast cancer.
Sutela A; Vanninen R; Sudah M; Berg M; Kiviniemi V; Rummukainen J; Kataja V; Kärjä V
Acta Oncol; 2008; 47(1):38-46. PubMed ID: 17851859
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction.
Kim MA; Jung EJ; Lee HS; Lee HE; Jeon YK; Yang HK; Kim WH
Hum Pathol; 2007 Sep; 38(9):1386-93. PubMed ID: 17555797
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
20. Human epidermal growth factor receptor 2 testing recommendation.
Raji A
J Clin Oncol; 2007 Sep; 25(25):4020-1; author reply 4021-3. PubMed ID: 17761990
[No Abstract] [Full Text] [Related]
[Next] [New Search]
